Psych CASC / OSCE · Consultation-liaison psychiatry
Explaining dementia diagnosis, BPSD plan, and antipsychotic caution to family — CASC communication station
MRCPsych/FRANZCP-style station: explain major NCD in plain language, non-drug BPSD plan, cholinesterase inhibitor expectations, antipsychotic mortality caution, and capacity/placement principles without jargon dumps.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar. The medical team has asked you to speak with the son. [1]
Candidate instructions. Explain dementia/major neurocognitive disorder in accessible language; describe why acute hospital agitation may be delirium on dementia; outline non-drug first steps for behavioural symptoms; set realistic expectations for cognitive enhancers; explain why antipsychotics are not routine and carry increased mortality risk; discuss planning for supports and decision-making without inventing legal section numbers. [2][3][4][5]
Candidate scenario
Son: “They said Mum has dementia and they want to drug her so she is quiet. Will tablets reverse this? If she goes to a home, is that because we failed her? She still says she wants to go home — does anyone listen?” Pneumonia is improving; she remains disoriented at night. [3]
Marking domains
- Empathy, structure, no defensiveness
- Clear explanation of progressive cognitive disorder affecting independence
- Delirium-on-dementia concept for acute worsening
- Non-drug BPSD plan first (environment, pain, infection, routine, carer approaches)
- Honest AChEI/memantine: modest symptomatic benefit, not a cure
- Antipsychotic: last-line, short-term, increased death risk — not for convenience sedation
- Capacity is decision-specific; home vs care is about safety and supports, not family failure
- Check understanding and offer written follow-up [1][2][3][5]
Reveal assessor key
Open. Introduce role, acknowledge fear and anger: “You are right to question medicines and placement — those are big decisions.” [1]
Explain diagnosis. “The team thinks your mother has a dementia — a condition where thinking skills decline enough that everyday independence is affected. We look at the pattern over months to years, not one bad hospital night.” [1]
Acute behaviour. “In hospital, infection, pain, strange environment, and disrupted sleep can cause an acute confusional state on top of dementia. Treating pneumonia and settling the environment often helps more than psychiatric sedatives.” [3]
Non-drug plan. “We prioritise comfort, familiar faces, hearing aids, toilets, pain relief, and calm routines. Medicines for behaviour are not the first step.” [3]
Cognitive drugs. “If this is Alzheimer-type disease, tablets such as donepezil or, in later stages, memantine can give modest help with thinking or function for some people. They do not reverse the disease. We start low, watch for side effects like stomach upset or slow pulse, and review whether they help.” [4]
Antipsychotic caution. “Antipsychotics are not routine ‘dementia sedatives’. Studies show a higher risk of death in older people with dementia who take them. We use them only if someone is severely distressed or unsafe after other measures, at the lowest dose for the shortest time, and we talk that risk through openly.” [2]
Home and capacity. “Wanting to go home matters. We assess decision-making for each issue — understanding options, appreciating risks, weighing them, and expressing a choice. If she cannot decide about a complex plan, the law uses substitute decision-makers in a least-restrictive way. Placement is about safety and support needs, not blame.” [5]
Close. Summarise, invite questions, offer leaflet/memory clinic follow-up, named contact. [1]
References
- [1]Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet, 2020.PMID 32738937
- [2]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
- [3]Kales HC, Gitlin LN, Lyketsos CG Assessment and management of behavioral and psychological symptoms of dementia BMJ, 2015.PMID 25731881
- [4]Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease N Engl J Med, 2012.PMID 22397651
- [5]Appelbaum PS, Grisso T Assessing patients' capacities to consent to treatment N Engl J Med, 1988.PMID 3200278